CD22 and melanoma: As early as 2013, a study on malignant melanoma demonstrated that tumor-induced Th2-type inflammation promotes the accumulation of CD22+ B cells and IgG4+ infiltrating cells within tumors, leading to the polarization of tumor-associated B cells to produce IgG4 (41, 42).